Efficacy of methimazole before the administration of radioactive iodine in the management of Graves’ disease
a systematic review and meta-analysis
Palavras-chave:
Methimazole, Graves disease, Elements, radioactive, HyperthyroidismResumo
BACKGROUND: The efficacy of anti-thyroid drugs in conjunction with radioactive iodine therapy in the management of Graves’ disease is still controversial. OBJECTIVE: To compare the efficacy of pretreatment with methimazole before the administration of radioactive iodine for the treatment of Graves’ disease. DESIGN AND SETTING: A systematic review and meta-analysis was conducted at a teaching/tertiary hospital in Ibadan, Nigeria. METHODS: A systematic search of the PubMed, Embase, Cochrane Library, and Web of Science databases was performed from inception to December, 2021. RESULTS: Five studies with 297 participants were included. There was no difference in the risk of persistent hyperthyroidism when radioactive iodine was used in conjunction with methimazole compared with when radioactive iodine was used alone (relative risk: 1.02, 95% confidence interval, CI: 0.62–1.66; P = 0.95, I2 = 0%). Subgroup analysis based on the duration between discontinuation of methimazole and the administration of radioactive iodine showed a lower risk of persistent hyperthyroidism when methimazole was discontinued within 7 days before radioactive iodine use, although this did not reach statistical significance (risk ratio: 0.85, CI: 0.28–2.58). CONCLUSIONS: The use of methimazole before radioactive iodine administration was not associated with an increased risk of persistent hyperthyroidism. Concerns about medication toxicity and adverse effects should be considered when clinicians make decisions on combination therapies for the treatment of Graves’ disease. PROSPERO REGISTRATION: CRD42020150013, https://www.crd.york.ac.uk/prospero/display_record. php?RecordID=150013.
Downloads
Referências
Davies TF, Ando T, Lin RY, Tomer Y, Latif R. Thyrotropin receptor-associated diseases: from adenomata to Graves disease. J Clin Invest. 2005;115(8):1972-83. PMID: 16075037; https://doi.org/10.1172/JCI26031.
Prabhakar BS, Bahn RS, Smith TJ. Current perspective on the pathogenesis of Graves’ disease and ophthalmopathy. Endocr Rev. 2003;24(6):802-35. PMID: 14671007; https://doi.org/10.1210/er.2002-0020.
Sundaresh V, Brito JP, Wang Z, et al. Comparative effectiveness of therapies for Graves’ hyperthyroidism: a systematic review and network meta-analysis. J Clin Endocrinol Metab. 2013;98(9):3671-7. PMID: 23824415; https://doi.org/10.1210/jc.2013-1954.
Parle JV, Maisonneuve P, Sheppard MC, Boyle P, Franklyn JA. Prediction of all-cause and cardiovascular mortality in elderly people from one low serum thyrotropin result: a 10-year cohort study. Lancet. 2001;358(9285):861-65. PMID: 11567699; https://doi.org/10.1016/S0140-6736(01)06067-6.
Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. Thyroid. 2016;26(10):1343-1421. PMID: 27521067; https://doi.org/10.1089/thy.2016.022.
Furszyfer J, Kurland LT, McConahey WM, Elveback LR. Graves’ disease in Olmsted County, Minnesota, 1935 through 1967. Mayo Clin Proc. 1970;45(9):636-44. PMID: 5469087.
Singer PA, Cooper DS, Levy EG. Treatment guidelines for patients with hyperthyroidism and hypothyroidism. Standards of Care Committee, American Thyroid Association. JAMA. 1995;273(10):808-12. PMID: 7532241.
Burch HB, Burman KD, Cooper DS. A 2011 survey of clinical practice patterns in the management of Graves’ disease. J Clin Endocrinol Metab. 2012;97(12):4549-58. PMID: 23043191; https://doi.org/10.1210/jc.2012-2802.
Hamilton HB, Werner SC. The effect of sodium iodide, 6-propylthiouracil, and 1-methyl-2-mercaptoimidazole during radioiodine therapy of hyperthyroidism. J Clin Endocrinol Metab. 1952;12(8):1083-94. PMID: 14946256; https://doi.org/10.1210/jcem-12-8-1083.
Cooper DS. Antithyroid drugs. N Engl J Med. 2005;352(9):905-17. PMID: 15745981; https://doi.org/10.1056/NEJMra042972.
Kahaly GJ, Bartalena L, Hegedüs L, et al. 2018 European Thyroid Association Guideline for the Management of Graves’ Hyperthyroidism. Eur Thyroid J. 2018;7(4):167-86. PMID: 30283735; https://doi.org/10.1159/000490384.
Brito JP, Payne S, Singh Ospina N, et al. Patterns of Use, Efficacy, and Safety of Treatment Options for Patients with Graves’ Disease: A Nationwide Population-Based Study. Thyroid. 2020;30(3):357-64. Erratum in: Thyroid. 2020;30(6):938. PMID: 31973681; https://doi.org/10.1089/thy.2019.0132.
Negro R, Attanasio R, Grimaldi F, et al. A 2015 Italian Survey of Clinical Practice Patterns in the Management of Graves’ Disease: Comparison with European and North American Surveys. Eur Thyroid J. 2016;5(2):112-19. PMID: 27493885; https://doi.org/10.1159/000444482.
Bonnema SJ, Bennedbaek FN, Veje A, Marving J, Hegedüs L. Continuous methimazole therapy and its effect on the cure rate of hyperthyroidism using radioactive iodine: an evaluation by a randomized trial. J Clin Endocrinol Metab. 2006;91(8):2946-51. PMID: 16735487; https://doi.org/10.1210/jc.2006-0226.
McDermott MT, Kidd GS, Dodson LE Jr, Hofeldt FD. Radioiodine-induced thyroid storm. Case report and literature review. Am J Med. 1983;75(2):353-9. PMID: 6349350; https://doi.org/10.1016/0002-9343(83)91217-2.
Hayek A. Thyroid storm following radioiodine for thyrotoxicosis. J Pediatr. 1978;93(6):978-80. PMID: 722446; https://doi.org/10.1016/s0022-3476(78)81226-8.
Sheeler LR, Skillern PG, Schumacher OP, Eversman JJ. Radioiodine-induced thyroid storm: a point of controversy. Am J Med. 1984;76(4):A98. PMID: 6546834; https://doi.org/10.1016/0002-9343(84)90305-x.
Reynolds LR, Kotchen TA. Antithyroid drugs and radioactive iodine. Fifteen years of experience with Graves’ disease. Arch Intern Med. 1979;139(6):651-3. PMID: 87156.
Connell JM, Hilditch TE, McCruden DC, Robertson J, Alexander WD. Effect of pretreatment with carbimazole on early outcome following radio-iodine (131I) therapy. Eur J Nucl Med. 1984;9(10):464-6. PMID: 6510423; https://doi.org/10.1007/BF00563170.
Andrade VA, Gross JL, Maia AL. Effect of methimazole pretreatment on serum thyroid hormone levels after radioactive treatment in Graves’ hyperthyroidism. J Clin Endocrinol Metab. 1999;84(11):4012-6. PMID:11502768; https://doi.org/10.1210/jcem.86.8.7707.
Braga M, Walpert N, Burch HB, Solomon BL, Cooper DS. The effect of methimazole on cure rates after radioiodine treatment for Graves’ hyperthyroidism: a randomized clinical trial. Thyroid. 2002;12(2):135-9. PMID: 11916282; https://doi.org/10.1089/105072502753522365.
Andrade VA, Gross JL, Maia AL. The effect of methimazole pretreatment on the efficacy of radioactive iodine therapy in Graves’ hyperthyroidism: one-year follow-up of a prospective, randomized study. J Clin Endocrinol Metab. 2001;86(8):3488-93. PMID: 11502768; https://doi.org/10.1210/jcem.86.8.7707.
Burch HB, Solomon BL, Cooper DS, et al. The effect of antithyroid drug pretreatment on acute changes in thyroid hormone levels after (131)I ablation for Graves’ disease. J Clin Endocrinol Metab. 2001;86(7):3016-21. PMID: 11443161; https://doi.org/10.1210/jcem.86.7.7639.
Pirnat E, Zaletel K, Gaberšček S, Hojker S. The outcome of 131I treatment in Graves’ patients pretreated or not with methimazole. Hell J Nucl Med. 2011;14(1):25-9. PMID: 21512661.
Karyampudi A, Hamide A, Halanaik D, Sahoo JP, Kamalanathan S. Radioiodine therapy in patients with Graves’ disease and the effects of prior carbimazole therapy. Indian J Endocrinol Metab. 2014;18(5):688-93. PMID: 25285287; https://doi.org/10.4103/2230-8210.139234.
Sabri O, Zimny M, Schulz G, et al. Success rate of radioiodine therapy in Graves’ disease: the influence of thyrostatic medication. J Clin Endocrinol Metab. 1999;84(4):1229-33. PMID: 10199759; https://doi.org/10.1210/jcem.84.4.5588.
Azizi F, Yousefi V, Bahrainian A, et al. Long-term continuous methimazole or radioiodine treatment for hyperthyroidism. Arch Iran Med. 2012;15(8):477-84. PMID: 22827783.
Kung AW, Yau CC, Cheng A. The incidence of ophthalmopathy after radioiodine therapy for Graves’ disease: prognostic factors and the role of methimazole. J Clin Endocrinol Metab. 1994;79(2):542-6. PMID:7913934; https://doi.org/10.1210/jcem.79.2.7913934.
Walter MA, Christ-Crain M, Schindler C, Müller-Brand J, Müller B. Outcome of radioiodine therapy without, on or 3 days off carbimazole: a prospective interventional three-group comparison. Eur j Nucl Med Mol Imaging. 2006;33(6):730-7. PMID: 16607544; https://doi.org/10.1007/s00259-006-0092-8.
Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. BMJ. 2009;339:b2535. PMID: 19622551; https://doi.org/10.1136/bmj.b2535.
Walter MA, Briel M, Christ-Crain M, et al. Effects of antithyroid drugs on radioiodine treatment: systematic review and meta-analysis of randomised controlled trials. BMJ. 2007;334(7592):514. PMID: 17309884; https://doi.org/10.1136/bmj.39114.670150.BE.
Tuttle RM, Patience T, Budd S. Treatment with propylthiouracil before radioactive iodine therapy is associated with a higher treatment failure rate than therapy with radioactive iodine alone in Graves’ disease. Thyroid. 1995;5(4):243-7. PMID: 7488862; https://doi.org/10.1089/thy.1995.5.243.
Hancock LD, Tuttle RM, LeMar H, Bauman J, Patience T. The effect of propylthiouracil on subsequent radioactive iodine therapy in Graves’ disease. Clin Endocrinol (Oxf). 1997;47(4):425-30. PMID: 9404440; https://doi.org/10.1046/j.1365-2265.1997.2741075.x.
Körber C, Schneider P, Körber-Hafner N, Hänscheid H, Reiners C. Antithyroid drugs as a factor influencing the outcome of radioiodine therapy in Graves’ disease and toxic nodular goitre? Eur J Nucl Med. 2001;28(9):1360-4. PMID: 11585295; https://doi.org/10.1007/s002590100565.
Oszukowska L, Knapska-Kucharska M, Makarewicz J, Lewiński A. The influence of thiamazole, lithium carbonate, or prednisone administration on the efficacy of radioiodine treatment ((131)I) in hyperthyroid patients. Endokrynol Pol. 2010;61(1):56-61. PMID: 20205105.
Marcocci C, Gianchecchi D, Masini I, et al. A reappraisal of the role of methimazole and other factors on the efficacy and outcome of radioiodine therapy of Graves’ hyperthyroidism. J Endocrinol Invest. 1990;13(6):513-20. PMID: 2258580; https://doi.org/10.1007/BF03348615.
Crooks J, Buchanan WW, Wayne EJ, Macdonald E. Effect of pretreatment with methylthiouracil on results of I-131 therapy. Br Med J. 1960;1(5167):151-4. PMID: 13812984; https://doi.org/10.1136/bmj.1.5167.151.
Kung AW, Yau CC, Cheng AC. The action of methimazole and L-thyroxine in radioiodine therapy: a prospective study on the incidence of hypothyroidism. Thyroid. 1995;5(1):7-12. PMID: 7787438; https://doi.org/10.1089/thy.1995.5.7.
Sundaresh V, Brito JP, Wang Z, et al. Comparative effectiveness of therapies for Graves’ hyperthyroidism: a systematic review and network meta-analysis. J Clin Endocrinol Metab. 2013;98(9):3671-7. PMID: 23824415; https://doi.org/10.1210/jc.2013-1954.
Yu W, Wu N, Li L et al. Side Effects of PTU and MMI in the Treatment of Hyperthyroidism: A Systematic Review and Meta-Analysis. Endocr Pract. 2020;26(2):207-17. PMID: 31652102; https://doi.org/10.4158/EP-2019-0221.
Streetman DD, Khanderia U. Diagnosis and treatment of Graves disease. Ann Pharmacother. 2003;37(7-8):1100-9. PMID: 12841824; https://doi.org/10.1345/aph.1C299.
Burch HB, Cooper DS. Management of Graves Disease: A Review. JAMA. 2015;314(23):2544-54. Erratum in: JAMA. 2016;315(6):614. PMID: 26670972; https://doi.org/10.1001/jama.2015.16535.
Bahn Chair RS, Burch HB, Cooper DS, et al. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid. 2011;21(6):593-646. PMID: 21510801; https://doi.org/10.1089/thy.2010.0417.
Downloads
Publicado
Como Citar
Edição
Seção
Licença
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
